In a market crowded with early-stage medical device companies promising incremental improvements, Inspira Technologies (NASDAQ: IINN) stands out for a different reason. Rather than focusing on a single product or…
Posts published in “Wall Street Wire”
Newly announced expanded OPKO partnership set to advance oral hypoparathyroidism treatment candidate toward the clinic, adding momentum to a pipeline already approaching Phase 3 in osteoporosis Entera Bio’s latest announcement…
With fiber installation costs hitting $77,000 per home in some federally funded rural deployments, this microcap’s hybrid technology could help carriers connect far more households with the same grant money.…
Purple Biotech’s CAPTN-3 platform uses conditionally activated tri-specific antibody technology, part of a broader class of multispecific antibodies that has commanded $700 million+ upfront payments and multi-billion-dollar transactions across the…
Modern medicine has gotten remarkably good at developing drugs that work – and far less consistent at ensuring they’re used quickly and correctly in the real world. Needle fear remains…
For the biggest drug companies in the world, the holy grail in cancer treatment isn’t just shrinking tumors – it’s keeping them from coming back. Right now, the most commercially…
As investors look for new areas of growth in healthcare, women’s health has become a rising theme. One of the biggest and least discussed conditions in this space is osteoporosis,…
The cannabis industry may be approaching a pivotal regulatory moment. Major U.S. media outlets have reported that President Trump is considering an executive order that would direct federal agencies to…
As burn injuries rise from combat, disasters, and industrial accidents, one company’s enzymatic product has become so effective that the U.S. government is buying and stockpiling it for national emergencies.…
Past winners like Nalu Medical, BigHat, and Syncell later advanced to major partnerships and M&A deals. PolyPid’s (NASDAQ: PYPD) Phase 3 results now place it on similar footing In biotech,…